Taysha Gene Therapies’ (TSHA) “Market Outperform” Rating Reaffirmed at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Taysha Gene Therapies (NASDAQ:TSHAFree Report) in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a $5.00 target price on the stock.

A number of other equities analysts have also recently weighed in on the stock. Canaccord Genuity Group restated a buy rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Piper Sandler assumed coverage on shares of Taysha Gene Therapies in a research report on Tuesday, April 9th. They set an overweight rating and a $9.00 price objective for the company. Needham & Company LLC restated a buy rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, June 17th. Cantor Fitzgerald restated an overweight rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday. Finally, Chardan Capital reiterated a buy rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, June 18th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Taysha Gene Therapies presently has a consensus rating of Buy and a consensus price target of $7.00.

View Our Latest Report on TSHA

Taysha Gene Therapies Stock Performance

TSHA opened at $2.96 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.38 and a quick ratio of 3.38. The firm has a fifty day moving average price of $2.99 and a 200 day moving average price of $2.40. Taysha Gene Therapies has a 1 year low of $0.50 and a 1 year high of $4.32. The stock has a market cap of $553.58 million, a P/E ratio of -6.04 and a beta of 0.50.

Taysha Gene Therapies (NASDAQ:TSHAGet Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The firm had revenue of $3.41 million during the quarter, compared to analysts’ expectations of $3.70 million. During the same period in the previous year, the business posted ($0.28) EPS. Equities research analysts anticipate that Taysha Gene Therapies will post -0.43 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TSHA. Artal Group S.A. boosted its stake in shares of Taysha Gene Therapies by 0.7% in the 1st quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock valued at $10,583,000 after buying an additional 24,444 shares during the period. Avoro Capital Advisors LLC raised its holdings in Taysha Gene Therapies by 328.2% in the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after acquiring an additional 14,294,445 shares in the last quarter. StemPoint Capital LP purchased a new position in Taysha Gene Therapies in the first quarter worth approximately $3,122,000. Quantum Private Wealth LLC grew its holdings in Taysha Gene Therapies by 9.2% during the 1st quarter. Quantum Private Wealth LLC now owns 698,520 shares of the company’s stock worth $2,005,000 after acquiring an additional 59,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Taysha Gene Therapies by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock valued at $103,000 after purchasing an additional 14,286 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Articles

Analyst Recommendations for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.